BC Week In Review | Jun 13, 2016
Financial News

Protalex amends follow-on

Protalex Inc. (OTCQB:PRTX), New Hope, Pa.   Business: Autoimmune   Date announced: 2016-06-03   Type: Follow-on   To be raised: TBD   Shares: TBD   Price prior: $5.21   Underwriter: Chardan Capital Markets   Note:...
BC Week In Review | May 9, 2016
Clinical News

PRTX-100: Preliminary Phase I/II data

Preliminary data from 8 patients with active RA in the per protocol (PP) population of part 1 of the 2-part, open-label, U.S. Phase I/II SPARTA-II (PRTX-100-105) trial showed that IV PRTX-100 for 6 months reduced...
BC Week In Review | May 9, 2016
Clinical News

PRTX-100: Phase Ib ongoing

Protalex will continue enrollment of the open-label, dose-escalation, French Phase Ib PRTX-100-203 trial evaluating 4 weekly doses of 3, 6, 12, 18 and 24 ug/kg IV PRTX-100 in up to 30 patients following a planned...
BC Week In Review | Mar 7, 2016
Clinical News

PRTX-100: Phase I/II ongoing

An independent safety monitoring committee recommended continuation of the open-label, dose-escalation, U.S. Phase I/II PRTX-100-202 trial of once-weekly IV PRTX-100 for 4 weeks based on a planned interim data review. Patients will now receive the...
BC Week In Review | Jan 18, 2016
Clinical News

PRTX-100: Phase Ib started

Protalex began the open-label, dose-escalation, French Phase Ib PRTX-100-203 trial to evaluate 4 weekly doses of IV PRTX-100 in up to 30 adults with persistent/chronic ITP. Protalex Inc. (OTCQB:PRTX), New Hope, Pa.   Product: PRTX-100...
BC Week In Review | Dec 21, 2015
Clinical News

PRTX-100: Phase I/II started

Protalex began the open-label, dose-escalation, U.S. Phase I/II PRTX-100-202 Study to evaluate 1, 3, 6, 12, 18 and 24 ug/kg IV PRTX-100 weekly for 4 weeks in up to 36 patients. Protalex Inc. (OTCQB:PRTX), New...
BC Week In Review | Mar 23, 2015
Clinical News

PRTX-100: Phase I/II started

Protalex began the open-label, U.S. Phase I/II PRTX-100-105 trial to evaluate 420 ug IV PRTX-100 weekly for 4 weeks in up to 12 patients who participated in the Phase Ib PRTX-100-104 trial and in 5...
BC Week In Review | Dec 8, 2014
Financial News

Protalex withdraws follow-on

Protalex Inc. (OTCBB:PRTX), New Hope, Pa.   Business: Autoimmune   Date announced: 2014-11-25   Type: Follow-on   Note: Protalex withdrew its proposed follow-on. The company filed to raise up to $26.3 million in February.  ...
BC Week In Review | Nov 24, 2014
Clinical News

PRTX-100: Additional Phase Ib data

Additional data from 61 patients with active RA in the first 5 cohorts of the double-blind, placebo-controlled, U.S. Phase Ib SPARTA (PRTX-100-104) trial showed that IV PRTX-100 plus methotrexate or leflunomide was well tolerated with...
BC Week In Review | Feb 17, 2014
Clinical News

PRTX-100: Interim Phase Ib data

Interim data from 41 patients with active RA in the first 4 cohorts of the double-blind, placebo-controlled, U.S. Phase Ib SPARTA (PRTX-100-104) trial showed that once-weekly 1.5, 3, 6 and 12 ug/kg doses of IV...
Items per page:
1 - 10 of 34
BC Week In Review | Jun 13, 2016
Financial News

Protalex amends follow-on

Protalex Inc. (OTCQB:PRTX), New Hope, Pa.   Business: Autoimmune   Date announced: 2016-06-03   Type: Follow-on   To be raised: TBD   Shares: TBD   Price prior: $5.21   Underwriter: Chardan Capital Markets   Note:...
BC Week In Review | May 9, 2016
Clinical News

PRTX-100: Preliminary Phase I/II data

Preliminary data from 8 patients with active RA in the per protocol (PP) population of part 1 of the 2-part, open-label, U.S. Phase I/II SPARTA-II (PRTX-100-105) trial showed that IV PRTX-100 for 6 months reduced...
BC Week In Review | May 9, 2016
Clinical News

PRTX-100: Phase Ib ongoing

Protalex will continue enrollment of the open-label, dose-escalation, French Phase Ib PRTX-100-203 trial evaluating 4 weekly doses of 3, 6, 12, 18 and 24 ug/kg IV PRTX-100 in up to 30 patients following a planned...
BC Week In Review | Mar 7, 2016
Clinical News

PRTX-100: Phase I/II ongoing

An independent safety monitoring committee recommended continuation of the open-label, dose-escalation, U.S. Phase I/II PRTX-100-202 trial of once-weekly IV PRTX-100 for 4 weeks based on a planned interim data review. Patients will now receive the...
BC Week In Review | Jan 18, 2016
Clinical News

PRTX-100: Phase Ib started

Protalex began the open-label, dose-escalation, French Phase Ib PRTX-100-203 trial to evaluate 4 weekly doses of IV PRTX-100 in up to 30 adults with persistent/chronic ITP. Protalex Inc. (OTCQB:PRTX), New Hope, Pa.   Product: PRTX-100...
BC Week In Review | Dec 21, 2015
Clinical News

PRTX-100: Phase I/II started

Protalex began the open-label, dose-escalation, U.S. Phase I/II PRTX-100-202 Study to evaluate 1, 3, 6, 12, 18 and 24 ug/kg IV PRTX-100 weekly for 4 weeks in up to 36 patients. Protalex Inc. (OTCQB:PRTX), New...
BC Week In Review | Mar 23, 2015
Clinical News

PRTX-100: Phase I/II started

Protalex began the open-label, U.S. Phase I/II PRTX-100-105 trial to evaluate 420 ug IV PRTX-100 weekly for 4 weeks in up to 12 patients who participated in the Phase Ib PRTX-100-104 trial and in 5...
BC Week In Review | Dec 8, 2014
Financial News

Protalex withdraws follow-on

Protalex Inc. (OTCBB:PRTX), New Hope, Pa.   Business: Autoimmune   Date announced: 2014-11-25   Type: Follow-on   Note: Protalex withdrew its proposed follow-on. The company filed to raise up to $26.3 million in February.  ...
BC Week In Review | Nov 24, 2014
Clinical News

PRTX-100: Additional Phase Ib data

Additional data from 61 patients with active RA in the first 5 cohorts of the double-blind, placebo-controlled, U.S. Phase Ib SPARTA (PRTX-100-104) trial showed that IV PRTX-100 plus methotrexate or leflunomide was well tolerated with...
BC Week In Review | Feb 17, 2014
Clinical News

PRTX-100: Interim Phase Ib data

Interim data from 41 patients with active RA in the first 4 cohorts of the double-blind, placebo-controlled, U.S. Phase Ib SPARTA (PRTX-100-104) trial showed that once-weekly 1.5, 3, 6 and 12 ug/kg doses of IV...
Items per page:
1 - 10 of 34